

TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: + 91 79 26599000 Fax: + 91 79 26582100 CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com

(Rs. in crores except per share data) Statement of Consolidated Financial Results for the Quarter and Half Year Ended 30-Sep-2019 Year ended Quarter ended (Unaudited) Half Year ended (Unaudited) Particulars (Audited) 30-Sep-2019 30-Jun-2019 30-Sep-2018 30-Sep-2019 30-Sep-2018 31-Mar-2019 Revenue 1968 1976 1858 3944 3692 7462 Net sales Other operating income 37 46 36 83 74 211 2005 Revenue from operations (net) 2022 1894 4027 3766 7673 10 Other income 34 20 54 37 57 2039 **Total revenue** 2042 1904 4081 3803 7730 Expenses Cost of materials consumed 331 376 271 707 595 1290 210 Purchases of stock-in-trade 210 238 420 486 846 Changes in inventories of finished goods, work-in-progress (27)39 (30)25 (3)83 and stock-in-trade Employee benefits expense 358 381 343 739 689 1404 116 122 126 238 248 504 Finance costs 160 Depreciation amortisation and impairment expense 163 152 323 302 618 1021 568 541 530 1109 2066 Other expenses **Total expenses** 1743 1763 1699 3506 3366 6811 Profit before exceptional items and tax 296 279 205 575 437 919 Exceptional items (Refer Note 8) 357 205 Profit before tax 296 279 575 437 562 Tax expense 72 158 125 280 **Current Tax** 74 84 (23)(20)(46)(43) (30)(155)Deferred Tax Short / (excess) provision of earlier periods* (1)52 63 26 115 95 126 Total tax expense 216 342 Net Profit for the period 244 179 460 436 Attributable to: - Owners of the company 244 216 179 460 342 436 Non controlling Interest * 0 0 0 Other Comprehensive Income (3)(9) (9) Items that will not be reclassified to profit or loss (6) (5) (6)Income tax relating to items that will not be reclassified to profit or loss 2 3 3 Items that will be reclassified to profit or loss (40)7 (125)(33)(198)54 Income tax relating to items that will be reclassified to profit 12 (3)32 57 (15)Total other comprehensive income (32)2 (96)(30)(145)33 **Total Comprehensive Income** 212 218 83 430 197 469 Attributable to: - Owners of the company 212 218 83 430 197 469 - Non controlling Interest * 0 0 0 Paid-up equity share capital (Face value of Rs. 5 each) 84.62 84.62 84.62 84.62 84.62 84.62 Paid up Debt Capital 2174 2815 1957 4988 4650 4639 Other Equity excluding Revaluation Reserves 5073 4735 4724 Networth **Debenture Redemption Reserve** 489 725 489 Earnings per share (of Rs. 5/- each) before exceptional items net of taxes (not annualised for the quarter): 12.74 10.57 27.22 20.23 14.48 42.45 Basic & Diluted Earnings per share (of Rs. 5/- each) after exceptional items net of taxes (not annualised for the quarter): **Basic & Diluted** 14.48 12.74 10.57 27.22 20.23 25.78 1.05 1.06 1.08 **Debt Equity Ratio** 1.23 1.80 1.19 **Debt Service Coverage Ratio** Interest Service Coverage Ratio 3.43 2.77 2.83



^{*} Less than Rs. 1 crore

Ratios have been computed as follows:-

a) Debt to Equity: Debt / Net Worth

Debt: Long term borrowings (Current & Non Current Portion)

Net worth: Share Capital + Reserves & Surplus

- b) Debt Service Coverage Ratio: EBIT / (Interest on term & working capital debt + Principal repayments of Long term debt)
 - (EBIT: Profit before Taxes +/(-) Exceptional Items + Interest Expense)
- c) Interest Service Coverage Ratio: EBIT / Interest Expense

Notes:

- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company, in their respective meetings held on 23-Oct-2019. The auditor have carried out review of the above said results. There is no qualification in the auditor's report on this statement of financial results.
- 2 The consolidated financial results include the financial results of sixteen wholly owned subsidiaries.
- 3 The Group operates in a single segment i.e Generic Formulation Business.
- 4 Consolidated Statement of Assets and Liabilities :

(Rs. in crores)

Unaudited Audite		
Particulars	As at	As at
Turitoului 3	30-Sep-2019	31-Mar-2019
	30 00p 2023	<u> </u>
ASSETS	ļ	
Non-current assets		
Property, plant and equipment	2731	2801
Right of use assets	149	· -
Capital work-in-progress	525	479
Goodwill	336	335
Other intangible assets	4417	4612
Intangible assets under development	153	138
		·
Financial assets		
Investments	2	2
Loans	2	3
Other financial assets	93	146
	97	151
Non-current tax assets (net)	96	120
Deferred tax assets (net)	407	370
Other non-current assets	30	77
Sub-total - Non-current assets	8941	9083
Current assets		
Inventories	1960	1935
	1500	1555
Financial assets		
Investments	449	351
Trade receivables	1518	1436
Cash and cash equivalents	415	589
Bank balances other than cash and cash	171	227
equivalents		
Loans	4	4
Other financial assets	117	65
	2674	2672
Other current assets	401	431
Non-current assets held for sale*	0	0
Sub-total - Current assets	5035	5038
TOTAL - ASSETS	13976	14121



		(Rs. in crores)
	Unaudited	Audited
Particulars	As at	As at
	30-Sep-2019	31-Mar-2019
EQUITY AND LIABILITIES		
Equity		
Share capital	85	85
Other Equity	4988	4639
Sub-total - Equity	5073	4724
Non-current liabilities		
Financial Liabilities		
Borrowings	3957	3913
Other financial liabilities	18	15
	3975	3928
Provisions	316	289
Deferred tax liabilities (net)	-	. 7
Other non-current liabilities	. 7	7
Sub-total - Non-current liabilities	4298	4231
Current liabilities		
Financial Liabilities		·
Borrowings	352	934
Trade payables		ļ
Due to micro and small enterprises	10	7
Due to others	1953	2091
Other financial liabilities	1708	1523
,	4023	4555
Provisions	410	414
Current tax liabilities (net)	82	79
Other current liabilities	90	118
Sub-total - Current liabilities	4605	5166
TOTAL - EQUITY AND LIABILITIES	13976	14121

Consolidated Cash Flow Statement

(Rs. in crores)

		(Rs. in crores)	
	Unaudited	Unaudited	
Particulars	Half year	Half year	
rai ticulai s	ended	ended	
· ·	30-Sep-2019	30-Sep-2018	
CASH FLOW FROM OPERATING ACTIVITIES			
PROFIT BEFORE TAX	575	437	
Adjustments for :			
Depreciation and amortization expense	323	302	
Allowance for doubtful trade receivables (net)	1	(3)	
Unrealised foreign exchange loss / (gain), net	(62)	13	
Loss on sale/discard/write-off of property, plant &	. 5	1	
equipments	3	_	
Net gain on sale of current investments	. (15)	(25)	
Finance cost	238	248	
Interest income	(5)	(8)	
OPERATING CASHFLOWS BEFORE WORKING CAPITAL	1060	965	
CHANGES	•		
Adjustments for changes in working capital:			
Trade receivables, loans and other assets	(22)	(142)	
Inventories	(25)	(66)	
Trade payables, liabilities and provisions	(167)	218	
CASH GENERATED FROM OPERATIONS	846	975	
Direct taxes paid	(130)	(159)	
NET CASH FROM OPERATING ACTIVITIES	716	816	



(Rs. in crores)

		(Rs. in crores)
-	Unaudited	Unaudited
Particulars	Half year	Half year
·	ended	ended
<u> </u>	30-Sep-2019	30-Sep-2018
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant & equipment and	•	,
Intangible assets	(149)	(160)
Proceeds from sale of property, plant & equipment		
and Intangible assets	1	C
Net gain on sale of current investments	15	25
Purchase of investment in equity shares	-	(2
Sale of government securities	-	15
	· -	13
Fixed deposits matured / (Investment in fixed	57	(61)
deposits) Interest received	7	4
interest received	·	4
NET CASH USED IN INVESTING ACTIVITIES	(69)	(179)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from long-term borrowings	550	250
Repayment of long-term borrowings	(409)	(142)
Net repayment of short term borrowings	(587)	(13)
Repayment of lease obligations	(16)	-
Dividend paid	(68)	(85)
Finance cost paid	(192)	(149)
NET CASH USED IN FINANCING ACTIVITIES	(722)	(139)
NET INCREASE / (DECREASE) IN CASH AND CASH	(75)	498
EQUIVALENTS		
Effect of exchange rate changes on foreign currency cash	4	· _
and cash equivalents	(1)	7
CACLL AND CACLL FOLUNIAL PAITS AT THE DECIMAINS OF		
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF PERIOD	940	702
PERIOD		
CASH AND CASH EQUIVALENTS AT THE END OF PERIOD	864	1207
		-
Note:-		
Cash and cash equivalents at the end of period	. :	
Cash and cash equivalents	415	515
Current investments in mutual funds	449	692
	864	1207

- The listed non-convertible debentures of the Parent Company aggregating Rs. 2174 crores as on 30-Sep-2019 (previous year ended Rs. 1957 crores) are secured by way of first pari passu charge created through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Parent Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
- Fiffective 01-Apr-2019, the Group has adopted Ind AS 116 Leases using modified retrospective approach. This has resulted in recognizing right of use assets and lease liability as on 01-Apr-2019. The adoption of the standard did not have any material impact to the financial results.
- Exceptional items for the year ended 31-Mar-2019 relates to impairment provision of certain intangible assets, intangible assets under development and goodwill recognised with respect to the acquisition of Bio-Pharm, Inc. (merged with Torrent Pharma Inc. with effect from 01-Jan-2019) and product recalls made during the year ended 31-Mar-2019.
- The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

FOR TORRENT PHARMACEUTICOLS LIMITED

SAMIR MEHTA
Executive Chairman

Place : Ahmedabad, Gujarat Date : 23-Oct-2019

